{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2006"],"condition":["untreated patients with advanced colorectal cancer.","Colorectal cancer stage IV"],"disease":["Colorectal Cancer Stage Iv","Untreated Patients With Advanced Colorectal Cancer."],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2519979"],"location":["Italy"],"study_start_month":["6"],"keyword":["LEDERFOLIN*EV 1FL LIOF 175MG","CAMPTO*1FL 100MG/5ML","FLUOROURACILE TEVA*IV FL 5G","AVASTIN*INFUS 1FL 100MG"],"repository":["ECRIN MDR"],"study_status":["Ongoing"],"additional_accession":[]},"is_claimable":false,"name":"Bevacizumab+folfiri in untreated patients with advanced colorectal cance","description":"Primary objectives: Objectively confirmed response rate \nTime-to- progression","dates":{"creation":"2006-06-15"},"accession":"2519979","cross_references":{"EU Clinical Trials Register":["2006-002887-25"]}}